The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure.
Hartopo AB, Achyar AC, Bagaswoto HP, Saputra F, Mumpuni H, Kusumastuti DA, Triyono T, Sukorini U, Puspitasari M, Setianto BY, Rohman MS, Anshory M, Waranugraha Y, Kamila PA, Iskandar A, Susianti H, Bergman A, Knothe C, Antonini P, Di Somma S.
Hartopo AB, et al. Among authors: iskandar a.
ESC Heart Fail. 2025 Jan 14. doi: 10.1002/ehf2.15191. Online ahead of print.
ESC Heart Fail. 2025.
PMID: 39809577
Free article.